MOTS-c Levels Linked to Heart Attack Damage in Patients
Background
Acute myocardial infarction (AMI), commonly known as a heart attack, involves severe damage to heart muscle due to blocked blood flow, often followed by ischemia-reperfusion injury (IRI), which occurs when blood flow is restored to ischemic tissue and can paradoxically worsen cardiac damage. IRI contributes significantly to adverse outcomes post-AMI. This study aimed to investigate the association between serum levels of the mitochondrial-derived peptide MOTS-c and the severity of IRI in patients experiencing AMI.
Study Design
Results
The study revealed a significant inverse correlation between serum MOTS-c levels and the severity of myocardial ischemia-reperfusion injury (IRI). Patients with higher circulating MOTS-c levels consistently exhibited lower levels of cardiac injury markers and better cardiac function. Specifically, MOTS-c levels were significantly lower in patients diagnosed with severe IRI compared to those with mild IRI (p<0.001). Furthermore, MOTS-c levels demonstrated a high sensitivity of 0.890 (with a cutoff value of 326.65 [95% CI, 253.41-631.84]; and an area under the curve of 0.739 [95% CI, 0.647-0.832], P<0.001) in predicting the occurrence of unstable angina and acute myocardial infarction in the general population. This suggests MOTS-c could serve as a valuable biomarker for both predicting cardiac events and assessing IRI severity.
Why It Matters
This research highlights MOTS-c's potential as a novel and promising biomarker for assessing the severity of myocardial ischemia-reperfusion injury (IRI) in acute myocardial infarction (AMI) patients. Identifying patients at higher risk for severe IRI could enable more targeted and aggressive therapeutic interventions, potentially improving clinical outcomes. If further validated through prospective studies, measuring MOTS-c levels could become a routine diagnostic tool to guide personalized treatment strategies post-heart attack. Future research should explore whether exogenous MOTS-c administration could directly mitigate IRI in human clinical trials, building on existing preclinical evidence from rat heart models.